Public biotechnology company discovering and developing therapeutic antibodies for infectious and autoimmune diseases.
AbCellera's ability to synthesize antibodies targeting specific receptors demonstrates the siloed approach that digital twins will replace; its platform will be valuable but limited without whole-body proteomic simulation.